An Open-Label, Dose Titration Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046, A Sustained-Release Analogue of Vasoactive Intestinal Peptide, In Adult Subjects With Pulmonary Arterial Hypertension

Trial Profile

An Open-Label, Dose Titration Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046, A Sustained-Release Analogue of Vasoactive Intestinal Peptide, In Adult Subjects With Pulmonary Arterial Hypertension

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2018

At a glance

  • Drugs PB 1046 (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Sponsors PhaseBio Pharmaceuticals
  • Most Recent Events

    • 27 Feb 2018 Planned End Date changed from 28 Feb 2018 to 1 Sep 2018.
    • 27 Feb 2018 Planned primary completion date changed from 28 Feb 2018 to 1 Aug 2018.
    • 01 Nov 2017 According to a PhaseBio Pharmaceuticals media release, first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top